The patent protects Wearable Devices' innovative neural measurement of weight, torque, and force applied with multiple real-world use-cases for Brain-Computer Interfaces, Industry 4.0, and Extended Reality ...

Let's say you have some money in your pocket you want to invest, but you're not sure where to put it. Perhaps you're extra worried due to recent market volatility.I'm going to offer a solid investment suggestion, but first remember that any money you might need within five ( or, to be more ...

MONTRÉAL, March 17, 2025 /PRNewswire/ - Bell Canada ( "Bell" or the "Company" ) today announced the commencement of separate offers ( the "Offers" ) to purchase for cash any and all of the five series of outstanding notes of the series listed in the table below ( collectively, the "Notes" ) , up ...

Niu Technologies' Q4 revenue surged 71.1% YoY, driven by a 64.9% increase in e-scooter sales. Niu expects 2025 sales growth of 40%-70%, projecting 1.3M to 1.6M units sold. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.

Legendary investor, Warren Buffett's Berkshire Hathaway BRK BRK has amplified its investment in Japan's five leading trading companies What Happened: After successfully negotiating the removal of a 10% investment cap, Berkshire Hathaway has raised its stakes in these diverse trading companies.

RESTON, Va., March 17, 2025 /PRNewswire/ -- The National Contract Management Association ( NCMA ) is excited to announce Jennifer Covington as its new Vice President of Learning & Development.

Eneboparatide hits primary endpoint in AstraZeneca's Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca's Imfinzi for limited-stage small cell lung cancer, reducing the risk of death by 27% in ADRIATIC Phase 3 trial.

NEW YORK, March 17, 2025 ( GLOBE NEWSWIRE ) -- Tiziana Life Sciences, Ltd.

MIAMI and JERUSALEM, March 17, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( NASDAQ: OPK ) and Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the ...

The Annual Meeting is the foremost educational and scientific event for gynecologic oncologists Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancer Findings may reflect stenoparib's dual PARP/Wnt pathway ...